$1.41
N/A
Last update: Nov 10, 7:00 PM
Tvardi Therapeutics Inc
TVRDNASDAQ
Tvardi Therapeutics fell 66.3% from $4.19 to $1.41, behind the S&P 500's +9.8%. Its worst day was Jun 26 (−36.4%), and its low came Oct 30 at $0.79.
Nov 11, 2025 – Nov 10, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.59 beat the $-0.91 estimate on $0.00 revenue.
−3.1% · S&P 500 −1.7%
EPS of $-0.78 missed the $-0.56 estimate on $0.00 revenue.
Story events cover the past 12 months · Times ET
−5.7% · S&P 500 +0.8%
EPS of $-0.73 missed the $-0.70 estimate on $0.00 revenue.
−0.7% · S&P 500 +0.8%
Tvardi Therapeutics shares fell 36.4%, while the S&P 500 fell 0.7%.
−36.4%, the year's worst day · S&P 500 −0.7%
Tvardi Therapeutics closed at its highest level of the year, 19.3% above where the year started.
+61.3%, the year's best day · S&P 500 −0.3%
EPS of $-0.69 missed the $-0.64 estimate on $0.00 revenue.
+7.3% · S&P 500 −0.2%
Tvardi Therapeutics closed at its lowest level of the year, 81.1% below where the year started.
−8.1% · S&P 500 −1.8%
Where it ended: a close of $1.41 on Nov 10, 2026. Up next: Q3 2026 earnings on Nov 24, 2026 (EPS est. $-0.56).
Nothing in the past 12 months.
All TVRD dividend historyReplay the year: the line draws itself and stops at each of the 7 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for TVRD and SPY from Benzinga historical bars. Not investment advice.
